development capabilities, access new markets, and tap into the expertise of regional healthcare professionals. The partnership between Burjeel Holdings and BridgeBio Pharma is a prime example of this trend. By collaborating with local stakeholders in Abu Dhabi, they can leverage the advanced infrastructure and resources available in the Emirate to accelerate their research and development effort..
RevolKa Ltd., a biotech company, has announced the completion of its collaborative drug discovery project with Sumitomo Pharma Co. for rare diseases. The project was completed within the agreed time frame and lead candidates were identified using RevolKa's proprietary technology platform called aiProtein®, which integrates directed protein evolution technology with artificial intelligence (AI). ..
The Bespoke Gene Therapy Consortium, managed by the Foundation for the National Institutes of Health (NIH), has selected eight rare diseases for its clinical trials program. The consortium aims to accelerate gene therapy development targeting rare diseases with few therapeutic options. The BGTC will develop protocols for first-in-human trials for Charcot-Marie-Tooth disease type 4J, congenital h..
